Indications › Cardiovascular disease › exenatide

exenatide in cardiovascular disease

exenatide is not approved in the US for cardiovascular disease, and has 13 trials on file here in this condition. 9 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

13 registered trials study exenatide (Bydureon, Byetta) in cardiovascular disease. None has a scheduled reporting date on file.

Trials on file: 13
Active: 0
Active phase 3: 0
Participants in active trials: 0
Sponsors: 12
Scheduled readouts: 0

All trials on file

Every registered trial of exenatide grouped under cardiovascular disease, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial NCT02404376	Completed	P3	Hospital Universitari Vall d'Hebron Research Institute
Trial of EXenatide in Acute Ischaemic Stroke NCT03287076	Unknown	P2	Neuroscience Trials Australia
Exenatide for Myocardial Protection During Reperfusion Study NCT01938235	Unknown	P2	University Health Network, Toronto
Myocardial Protection of Exenatide in AMI NCT01580514	Completed	P4	Kyunghee University Medical Center
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI NCT00835848	Completed	P4	Copenhagen University Hospital, Rigshospitalet
Physical and Chemical Study of Atherosclerosis Mechanisms NCT01700075	Completed	P4	Nazarbayev University
Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients NCT00736229	Completed	P4	Saint Luke's Health System
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial) NCT01254123	Unknown	P3	Amsterdam UMC, location VUmc
Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects NCT02621489	Completed	P4	Karolinska Institutet
Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass NCT01373216	Completed	P3	Charles University, Czech Republic
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke NCT02829502	Unknown	P2	Christina Kruuse
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers NCT02838589	Completed	P2	Christina Kruuse
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults NCT00845559	Withdrawn	P4	Yale University

See the full record for exenatide, or every molecule being studied in cardiovascular disease. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.